Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

BILIVERDIN REDUCTASE-A IN BRAIN INSULIN SIGNALING AND OXIDATIVE STRESS- MEDIATED NEURODEGENERATION

BVRINSULINAD

Alzheimer disease (AD) is the most common form of dementia among the elderly, whose care in Europe demands an amount of financial resources which is rising dramatically making AD a financial problem. Delaying AD onset by 5 years would decrease its prevalence by 50% with an enormous impact on the financial resources involved in AD care. Hence, it is...

Funding Programme
Start Date
End Date
Total Funding
€ 179 740
European Countries Involved

Bioactive compounds from blackcurrant processing waste for brain health

BRAINHEALTHFOOD

Alzheimer's disease (AD) is the most common age-related neurodegerative disorder, and one of the most devastating diagnoses that patients and their families can receive. Currently ~10 % of over 65 year old have AD, and the direct and indirect cost of its care is estimated to be >100 billion $ in the US alone and in the UK ~ €22M, and therefore...

Funding Programme
Start Date
End Date
Total Funding
€ 1 139 467
European Countries Involved

Bioengineered microbes as a platform for discovering chemical rescuers of disease-related misfolding of integral membrane proteins

ProMisMe

Protein misfolding diseases (PMDs) are a large group of human disorders caused by the misfolding of specific proteins. They include conditions with high socio-economic impact, such as Alzheimer’s disease, cystic fibrosis, obesity and type 2 diabetes, and the majority of them remain incurable. Among the >70 PMDs, about 1/3 are caused by misfolding...

Funding Programme
Start Date
End Date
Total Funding
€ 211 658
European Countries Involved

Biological Resource Analysis to Identify New Mechanisms and phenotypes in Neurodegenerative Diseases

BRAIN-MEND

Neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementia, corticobasal degeneration, multiple system atrophy and progressive supranuclear palsy. We currently classify and treat these conditions based on symptoms and clinical findings. Although this approach seems logical, it...

Funding Programme
Start Date
End Date
Total Funding
€ 2 100 000
European Countries Involved

Biomarker based diagnosis of rapid progressive dementias – optimisation of diagnostic protocols.

DEMTEST

DEMTEST has established a large European and global collaboration between national surveillance units and dementia research centres, facilitating cooperation between neurologists, neuropathologists and neuroscientists. We work on standardisation of tests that are currently available and harmonise their use between centers worldwide. We define...

Funding Programme
Start Date
End Date
Total Funding
€ 2 200 000

Biomarker Development for Postoperative Cognitive Impairment in the Elderly

BioCog

Postoperative delirium (POD) is characterized by the progressive deterioration of sensory/cognitive function after surgery with incidences of up to 30-80%. It is frequently followed by postoperative cognitive dysfunction (POCD) which tends to persist over time. In elderly patients, POCD resembles chronic dementia and appears to accelerate the...

Funding Programme
Start Date
End Date
Total Funding
€ 7 743 063
European Countries Involved

Biomarkers for Alzheimer’s disease and Parkinson’s disease.

BIOMARKAPD

Neurodegenerative disorders, represented mostly by Alzheimer's disease (AD) and Parkinson's disease (PD), are characterised by progressive neuronal impairment and death. In spite of the brain's known capacity for regeneration, lost neurons generally cannot be replaced. Therefore, drugs aimed at inhibiting neurodegenerative processes are likely to...

Funding Programme
Start Date
End Date
Total Funding
€ 449 066

Biophysical Modeling and Analysis of Dynamic Medical Images

MEDYMA

During the past decades, exceptional progress was made with in vivo medical imaging technologies to capture the anatomical, structural and physiological properties of tissues and organs in a patient, with an ever increasing spatial and temporal resolution. The physician is now faced with a formidable overflow of information, especially when a...

Funding Programme
Start Date
End Date
Total Funding
€ 2 498 327
European Countries Involved

Blood Biomarker-based Diagnostic Tools for Early Stage Alzheimer’s Disease

BBDiag

Alzheimer’s disease (AD) affects more than 7 million people in Europe and this figure is expected to double every 20 years. Despite intensive efforts, no disease-modifying treatments or preventive strategies are available. The lack of specific, sensitive and minimally invasive diagnostics to identify people with early-stage AD to be included in...

Funding Programme
Start Date
End Date
Total Funding
€ 3 465 708
European Countries Involved

Blood microRNAs ADAM10-target: novel diagnostic and prognostic biomarkers for Alzheimer's disease by electrochemical sensors

mirADAM

ADAM10 (A Disintegrin and Metalloprotease 10), the main α-secretase of the non-amyloidogenic cleavage of the amyloid precursor protein (APP), is a common player in Type 2 diabetes (T2D) and Alzheimer´s disease (AD). ADAM10 levels are altered in platelets, plasma, serum, and CSF of elderly with AD, suggesting its potential role as an AD biomarker...

Funding Programme
Start Date
End Date
Total Funding
€ 90 576
European Countries Involved

blood Proteins for early Discrimination of dEmentias

bPRIDE

Dementia is a group of disorders characterized by severe memory loss ultimately impairing daily life activities. Major forms are Alzheimer’s disease, Lewy body dementia, and frontotemporal dementia. Each dementia type is caused by different biological factors and therefore requires a specific treatment targeting these factors. To develop effective...

Funding Programme
Start Date
End Date
Total Funding
€ 1 800 000
European Countries Involved

Brain barriers training

BtRAIN

The brain barriers function to protect the central nervous system (CNS) from neurotoxic compounds. By the same traits they unfortunately block delivery of drugs to the CNS thus hindering proper diagnosis and effective treatment of neurological disorders including Alzheimer’s disease and multiple sclerosis. The unusual complexity of the brain...

Funding Programme
Start Date
End Date
Total Funding
€ 3 067 402
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).